Management of Borderline ovarian tumours
Borderline ovarian tumours (BOT) are defined as growths
that have some, but not all, characteristics of malignant
ovarian tumours. The decisive characteristic is the lack of
a destructive invasion of the stroma. In most cases, ovarian
carcinoma is in stage III/IV when diagnosed, while most
BOT are diagnosed in stage I/II. The overall 15-year survival
rate is around 99% for BOT diagnosed in stage I/II, falling
to 30–50% for those diagnosed in stage III. In the presence
of BOT, so-called peritoneal implants are frequently described,
which are found at the outer surface with primary
proliferations in 70–80% of cases. When implants are
found it is important to determine their nature. Most
implants are noninvasive, but in 6–10% of patients they
are invasive, substantially lowering the survival rate.
The therapy leans heavily on the clinical management of
ovarian carcinoma and is directed at definitive staging,
i. e. complete or maximum debulking. As the women affected
are often young, it is essential to take account of any
desire for children when surgery is planned and carried out.
Routine performance of lymphadenectomy even when the
lymph nodes are unremarkable cannot be recommended.
As a rule no adjuvant therapy is indicated. Some authors
recommend platinumcontaining chemotherapy if residual
tumour persists after surgery or in the case of recurrence.
After-care should continue to the end of each patient?s life.
CME Prakt Fortbild Gynakol Geburtsmed Gynakol
Endokrinol 2016; 12(2): 172–183
Borderline ovarian tumour, management of borderline,
prognose of borderline ovarian tumour, diagnosis of
borderline ovarian tumour, treatment of borderline
Luisa Kretzschmar1, Carsten Denkert2, Jalid Sehouli1
1 Klinik für Gynäkologie, Charité – Universitätsmedizin Berlin, Berlin
2 Institut für Pathologie, Charité – Universitätsmedizin Berlin, Berlin
Reviewer: Oumar Camara, Bad Langensalza,
und Jacek Grabowski, Berlin
Kretschmar L. Therapiemanagement ... Gynakol Geburtsmed Gynakol Endokrinol 2016; 12(2): 172–183 publiziert 31.7.2016 www.akademos.de/gyn ©akademos Wissenschaftsverlag 2016 ISSN 1614-8533